Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M4, and Amyloid-beta protofibril (CHRM1, CHRM4, and Aβ)

KarXT + lecanemab refers to a therapeutic combination of two distinct agents: a muscarinic receptor agonist and an anti-amyloid monoclonal antibody. KarXT (xanomeline and trospium chloride) targets the muscarinic acetylcholine receptors M1 and M4, which are G protein-coupled receptors involved in cognitive processing and the regulation of dopamine release [FDA, 2024; Paul et al., 2022]. By activating these receptors, KarXT aims to alleviate psychotic symptoms and potentially improve cognitive function in neurodegenerative and psychiatric disorders. Lecanemab is a humanized IgG1 monoclonal antibody that selectively binds to soluble amyloid-beta (Aβ) protofibrils, which are considered highly toxic species in the pathogenesis of Alzheimer's disease [van Dyck et al., 2023]. Its primary role is to facilitate the clearance of these aggregates to slow the progression of cognitive and functional decline [FDA, 2023]. Together, this combination addresses both the symptomatic neuropsychiatric burden and the underlying proteinopathy associated with Alzheimer's disease. This dual approach is of significant interest to the biotechnology industry as it seeks to integrate disease-modifying therapies with advanced symptomatic treatments.

Other names

KarXT and LecanemabXanomeline/Trospium and LecanemabCobenfy and Leqembi

KarXT (xanomeline/trospium) acts as a dual M1/M4 muscarinic acetylcholine receptor agonist to modulate neurotransmission, while lecanemab is a monoclonal antibody that binds to and clears amyloid-beta protofibrils from the brain.